New hope for brain lymphoma: experimental antibody targets Hard-to-Treat cancers

NCT ID NCT05485753

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 25 times

Summary

This study tests an experimental drug called GNC-038 in people with central nervous system lymphoma that has come back or not responded to treatment. The drug is a special antibody designed to attack cancer cells in the brain and spinal cord. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 7 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Beijing GoBroad Boren Hospital

Beijing, Beijing Municipality, China
Beijing Tiantan Hospital, Capital Medical University

Beijing, Beijing Municipality, 100070, China
Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Conditions

Explore the condition pages connected to this study.

PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA